{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"632nm","title":"AI, Cancer Vaccines, and the Future of Personalized Medicine | Sid Sijbrandij on GitLab + Biotech","html":"","width":"100%","height":180,"duration":6042,"description":"Can AI help design personalized cancer vaccines?\nVisit Future of Cancer Care Today: https://sijbrandijfoundation.org/fcct\nIn this episode, we speak with Sid Sijbrandij, founder of GitLab who went \"Founder Mode\" against his own cancer. Sid discusses personalized cancer vaccines, tumor sequencing, immunotherapy, and the challenge of making cutting-edge cancer treatments accessible to patients outside traditional clinical trials.\nWe explore how personalized mRNA cancer vaccines work, from sequencing a tumor and identifying mutations that distinguish cancer cells from healthy cells to selecting tumor-specific antigens that can be encoded into an mRNA vaccine. Sid explains why this approach is fundamentally different from conventional chemotherapy and why engaging the patient's own immune system could give immunotherapies the potential to produce durable or even curative responses.\nSid also describes his own experience combining multiple experimental treatment modalities, including personalized mRNA vaccines, immunotherapies, and radioligand therapy. He explains how radioligands can use molecular binders to selectively deliver radiation to tumor tissue, and how modifying the tumor microenvironment may make cancers more susceptible to subsequent immune therapies.\nWe also discuss why personalized cancer vaccines remain difficult and expensive to manufacture. In melanoma, recent clinical trials have demonstrated that individualized mRNA vaccines can target dozens of tumor-specific antigens, with surprisingly little overlap between patients. This creates a fundamentally different manufacturing problem from producing a conventional drug at scale: every patient's vaccine may need to be designed and manufactured separately.\nFinally, Sid explains his effort to make these technologies more accessible through a network of biotech companies. He describes the economics and logistics of producing personalized cancer vaccines, including his experience reducing the time and cost...","thumbnail_url":"https://img.transistorcdn.com/GydlQqnUybBqv7mvA947eCIsz_CyOG8rEnboLv3Hs_I/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yOGMz/YTliMThlODIyYzYw/OGVjOWNiZWNlNmQ1/ZmQ0Ni5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}